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An increase in peripheral blood eosinophil count is observed
in some diseases including allergic/atopic diseases, parasitic dis-
eases, and malignancies.1,2 Hypereosinophilia-associated dis-
eases (HEADs) show eosinophil inﬁltration into some organs
resulting in an organ injury.3 The severity of eosinophilia associ-
ated with these diseases varies widely.4 In 1994, Wardlaw classi-
ﬁed eosinophilia into mild (1000e1500/mL), moderate
(1500e5000/mL), and severe (5000/mL), but the report did not
present any basis for this classiﬁcation.5 To differentiate HEADs
from atopic diseases, Kobayashi et al. reported a cutoff count of
2052/mL;3 HEADs clearly showed a substantially higher count
than atopic diseases. Furthermore, Nakachi et al. indicated that
non-episodic angioedema with eosinophilia (NEAE) usually de-
velops with severe eosinophilia reaching to a count of 10000/
mL.6 Taking these into consideration, the severity of eosinophilia
might serve as a useful indicator for an early tentative diagnosis.
This study aimed at clariﬁcation of the relationship between pe-
ripheral eosinophil count and incidence of a HEAD to make a
quick diagnosis.
The blood samples from the patients who were 20 years of age
and older examined for the complete blood cell count and differ-
ential count in our hospital between January 2006 and March
2013. Eosinophil count was measured using SE-5000 and SE-
2100 (Sysmex, Kobe, Japan). The patients with an eosinophil
count of 2000/mL were enrolled and examined for their
maximum eosinophil count, diagnosis of eosinophilia-related dis-
ease, and steroid dose at the sampling for the maximum count.
For each patient's disease course, the maximum eosinophil count
was used in the analysis regardless of treatment. The diagnoses
were based on clinical records. According to their diagnoses,
the patients were classiﬁed into ten groups: skin diseases
including atopic dermatitis and urticaria, NEAE, solid tumors
including lung cancer, digestive tract cancer, hepatobiliary cancer,
pancreas cancer, brain cancer, breast cancer, uterus cancer and
renal cancer, hematological tumors including leukemia, lym-
phoma, multiple myeloma, amyloidosis, myelodysplastic syn-
dromes and idiopathic thrombocytopenic purpura, bronchialPeer review under responsibility of Japanese Society of Allergology.
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licenses/by-nc-nd/4.0/).asthma, eosinophilic granulomatosis with polyangiitis (EGPA),
mono-organ involvement associated with eosinophilia, drug re-
actions including drug-induced eruption and hepatitis, parasitic
diseases, and others. As for patients with solid or hematological
tumor, if their peripheral eosinophilia were clearly related to
the side effect of their treatment, they were classiﬁed into drug
reactions. Mono-organ involvement associated with eosinophilia
was deﬁned as an organ injury considered to be caused by eosin-
ophilic inﬁltration.
During the study period, 845439 blood samples were exam-
ined. Among these samples, 1137 (0.13%) showed an eosinophil
count of 2000/mL and 62 (0.007%) showed a count of 10000/
mL. As for samples with a count of 2000/mL, the number of sam-
ples at each 1000/mL interval is shown in Figure 1. 1134 samples
with a count of 2000/mL were from 442 patients (248 males
and 194 females) aged 63.1 ± 17.3. The ratios of disease in pa-
tients with an eosinophil count of 2000/mL and 10000/mL are
shown in Figure 2. The number of patients and mean ± SD
maximum eosinophil count in each of ten groups were as follows:
n ¼ 70, 3676 ± 3018/mL in skin diseases; n ¼ 68, 3275 ± 3376/mL
in solid tumors; n ¼ 51, 4631 ± 3217/mL in drug reactions; n ¼ 37,
3808 ± 2355/mL in hematological tumors; n ¼ 36, 5711 ± 3332/mL
in mono-organ involvement associated with eosinophilia (pneu-
monia; 66.7%, gastroenteritis; 8.3%, sinusitis; 8.3%, serositis;
5.6%, myocarditis; 5.6%, others; 5.6%); n ¼ 23, 8412 ± 8121/mL
in NEAE; n ¼ 16, 8290 ± 6428/mL in EGPA; n ¼ 15,
2919 ± 1157/mL in bronchial asthma; n ¼ 6, 3898 ± 1821/mL in
parasitic diseases; and n ¼ 116, 3291 ± 2065/mL in others. Others
consist mainly of transient eosinophilia of unknown causes dur-
ing treatment of various diseases. Only 28 patients showed a
maximum count of 10000/mL; the major diagnoses were EGPA
(n ¼ 7, 25.0%), NEAE (n ¼ 4, 14.3%), and mono-organ involvement
associated with eosinophilia (n ¼ 5, 17.8%). As for the steroid
regimen, among the 442 patients with eosinophil counts of
2000/mL, 49 patients (11.1%) were administered prednisolone
(PSL) (1.3 ± 5.0 mg/day) at the sampling, and 34 (8.2%) had PSL
at a dose of 5 mg/day.
This study was focused on the severity of the peripheral blood
eosinophilia. Among over the 800000 samples, only 0.13% of sam-
ples showed an eosinophil count of 2000/mL, and only 0.007%
showed a count of 10000/mL. An eosinophil count of 10000/
mL was associated with a few diseases, namely EGPA, NEAE and
mono-organ involvement associated with eosinophilia. For the
differential diagnosis of HEADs, an eosinophil count of 10000/vier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Fig. 1. The number of samples with a peripheral blood eosinophil count of 2000/mL.
The sample number at each 1000/mL interval is shown.
Fig. 2. a) The ratio of diseases in patients with an eosinophil count of 2000/mL. b) The ratio of diseases in patients with an eosinophil count of 10000/mL. EGPA, eosinophilic
granulomatosis with polyangiitis; NEAE, non-episodic angioedema with eosinophilia.
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mentioned diseases. On the other hand, patients with an eosino-
phil count of 2000e10000/mL have more differential diagnoses
than a count of 10000/mL. In this study, more than half of pa-
tients with a count of 2000/mL belonged to the groups of skin
diseases, drug reactions and solid/hematological tumors. This
result suggests patients with an eosinophil count of
2000e10000/mL ﬁrstly should exclude skin diseases, drug reac-
tions and solid/hematological tumors.
Bronchial asthma rarely develops with severe eosinophilia
reaching to a count of 2000/mL, but this study included 15 cases.
Among 15 cases, four cases were examined at the asthmatic
attack and eight cases were complicated with other diseases.
Only three cases were examined without the attack or other
diseases.
Conceivably in developing countries, severe eosinophilia might
be often associated with parasitic diseases.7 But currently, parasitic
diseases seldom develop in Japan.8 Our hospital is a general hos-
pital, to which many patients with various diseases visit, butonly six of the 442 patients had eosinophilia related to parasitic
diseases.
The peripheral blood eosinophil count during the treatment of
corticosteroids, which usually decrease it, is not appropriate for
the argument about the usefulness of the count.9 However, in this
study, the maximum eosinophil count was observed without ste-
roid therapy in almost 90% of the patients, and only a few had
5 mg of PSL at the sampling. The use of corticosteroids would
not be a limitation of this study.
In conclusion, a peripheral blood eosinophil count of10000/mL
was observed only in a limited number of patients and in a few dis-
eases, mainly EGPA, NEAE andmono-organ involvement associated
with eosinophilia. It is useful to evaluate the maximum eosinophil
count for the presumptive diagnosis of HEADs.Conﬂict of interest
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